Registry Study of Pancreatic Irreversible Electroporation IRE Treatment for Pancreatic Cancer Patients Eligible for Soft Tissue Ablation

What this Trial Is About

Researchers are creating a registry to better understand treatment choices and outcomes for pancreatic cancer patients undergoing irreversible electroporation IRE, a type of soft tissue ablation. The study aims to gather evidence to help doctors provide the best care for patients with pancreatic tumors that cannot be surgically removed. This research also seeks to learn about the concerns, limitations, and complications experienced by earlier users of this treatment. The registry collects clinical and pathological data from multiple centers on patients with pancreatic neoplasms who are eligible for soft tissue ablation as determined by their doctors. Data entry is web-based and includes all treatments, follow-ups every 3-4 months in the first year and every 6 months in the second year, for up to two years or until death. Participating institutions submit detailed data and receive annual certificates acknowledging their contribution. Participants provide de-identified information about their treatment and outcomes, monitored for adverse events for up to five years. The registry supports quality assurance by reviewing outcomes and helping centers improve if needed. Researchers focus on adverse events and overall survival, gathering information to improve future ablation treatments for unresectable pancreatic tumors. The study duration allows comprehensive long-term follow-up and data analysis.

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry